Characterization and management of gastrointestinal (GI) adverse events (AEs) with zanidatamab + chemotherapy (CT) ± tislelizumab in first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): Analysis from HERIZON-GEA-01.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Elena Elimova, Sun Young Rha, Kohei Shitara, Tianshu Liu, Josep Tabernero, Keun-Wook Lee, Michael Schenker, Niall C. Tebbutt, Jaffer A. Ajani, Norhidayu Salimin, Geoffrey Yuyat Ku, Jong Gwang Kim, Inmaculada Ales Diaz, Jingdong Zhang, Filippo Pietrantonio, Li-Yuan Bai, Samuel Le Sourd, Ye Chen, Jonathan E. Grim, Lin Shen
Institutions: Princess Margaret Cancer Centre, Yonsei University, Yonsei Cancer Hospital, National Cancer Center Hospital East, Fudan University, Zhongshan Hospital, Universitat de Vic - Universitat Central de Catalunya, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Seoul National University, Seoul National University Bundang Hospital, University of Medicine and Pharmacy of Craiova, Olivia Newton-John Cancer Wellness & Research Centre, Austin Health, The University of Texas MD Anderson Cancer Center, National Cancer Institute, Memorial Sloan Kettering Cancer Center, Kyungpook National University, Kyungpook National University Medical Center, Hospital Regional Universitario de Málaga, Liaoning Cancer Hospital & Institute, Fondazione IRCCS Istituto Nazionale dei Tumori, China Medical University, China Medical University Hospital, Centre Eugène Marquis, BeOne Medicines (Switzerland), Jazz Pharmaceuticals (United States), Peking University Cancer Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Jazz Pharmaceuticals
OpenAlex ID: W7162496498
Cites:
Cited by:
Related to: